For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | 2025-03-31 | ||
|---|---|---|---|---|
| Total revenue | 0 | - | ||
| Restructuring costs | 16,335 | - | ||
| Research and development expenses | 57,275 | 29,039 | ||
| General and administrative expenses | 10,181 | 10,982 | ||
| Total operating expenses | 83,791 | 40,021 | ||
| Loss from operations | -83,791 | -40,021 | ||
| Other (expense) income, net | -585 | -1,342 | ||
| Interest income | 6,382 | 6,950 | ||
| Research and development tax credits | 752 | 493 | ||
| Grant income | 183 | 407 | ||
| Loss before income taxes | -77,059 | -33,513 | ||
| Income tax expense | 1,670 | 1,100 | ||
| Net loss | -78,729 | -34,613 | ||
| Foreign currency translation adjustments | -1,217 | 846 | ||
| Unrealized gain (loss) on available-for-sale securities | -50 | 230 | ||
| Comprehensive loss | -79,996 | -33,537 | ||
| Earnings per share, basic, total | -1.81 | -0.8 | ||
| Earnings per share, diluted, total | -1.81 | -0.8 | ||
| Weighted average number of shares outstanding, basic, total | 43,564,573 | 43,241,341 | ||
| Weighted average number of shares outstanding, diluted, total | 43,564,573 | 43,241,341 | ||
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. (ITOS)